An observational study in Cholangiocarcinoma, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational
This is a prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of a novel serological risk model on blood samples in early diagnosis of cholangiocarcinoma patients.
A reliable and accurate preoperative tool capable of early diagnosing malignant cholangiocarcinoma is lacking and urgently needed for clinical practice. This study proposes to establish and evaluate a novel serological risk model on blood samples for non-invasively diagnosing cholangiocarcinoma. The study includes the construction of capable novel serological risk model and the validation of the diagnosis model.
930 studies on the registry are indexed under Cholangiocarcinoma; 292 are open to participants now.
This study's planned enrollment of 60 is below the median of 176 across 180 observational studies indexed under Cholangiocarcinoma.
Browse Cholangiocarcinoma studies →Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 477 studies on the registry; 278 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who had suspected cholangiocarcinoma and completed the blood collection before surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
Diagnostic Test: No interventions
No interventions
Malignant/Benign status of enrolled suspected cholangiocarcinoma patients by pathological examination
The pathological examination results of each enrolled patient will be recorded
Time frame: 4 weeks
Malignant/Benign status of enrolled suspected cholangiocarcinoma patients evaluated by the novel serological risk model
The novel serological risk model will be constructed for differential malignant/benign diagnosis
Time frame: 2 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →